Roche enters partnership with Alnylam for hypertension therapy
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
Swiss pharmaceutical group Roche said on Monday it had entered into a partnership with U.S. biopharmaceutical company Alnylam to co-develop and co-commercialise zilebesiran, a therapy to treat hypertension in patients with high cardiovascular risk.
:max_bytes(150000):strip_icc():format(jpeg)/PaperworkatDesk-1a3837aec527439dbbf86d99a89611ba.jpg "2024 and 2025 Federal Income Tax Brackets, Standard Deductions, and Tax Rates")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1245836826-2b88234057c442f7bf5538ddb7f7584a.jpg "What It Would Take for the U.S. Dollar To Collapse")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1336655800-0cde652f461b4771aa45601032b5420b.jpg "Home Equity Loans and Divorce")